Abstract
Tumor-associated antigens can be seen as unique targets for the delivery of anti-cancer therapy. Monoclonal antibodies directed at such antigens are increasingly being seen as important biologic reagents that will complement the group of existing cytotoxic drugs. This report briefly overviews recent advances in the field of monoclonal antibody therapy of cancer and provides insight regarding the promises and limitations of this novel therapeutic approach.
| Original language | English (UK) |
|---|---|
| Pages (from-to) | 214-224 |
| Number of pages | 11 |
| Journal | American Journal of the Medical Sciences |
| Volume | 304 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 1992 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Cancer
- Immunotherapy
- Monoclonal antibody
Fingerprint
Dive into the research topics of 'Advances in monoclonal antibody therapy of cancer'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver